Erratum: Comparison of bleeding risk and hypofibrinogenemia-associated risk factors between tigecycline with cefoperazone/sulbactam therapy and other tigecycline-based combination therapies
- PMID: 38288439
- PMCID: PMC10822909
- DOI: 10.3389/fphar.2024.1365927
Erratum: Comparison of bleeding risk and hypofibrinogenemia-associated risk factors between tigecycline with cefoperazone/sulbactam therapy and other tigecycline-based combination therapies
Abstract
[This corrects the article DOI: 10.3389/fphar.2023.1182644.].
Keywords: carbapenems; cefoperazone/sulbactam; coagulation disorders; hypofibrinogenaemia; tigecycline; β-lactam antibiotics.
Copyright © 2024 Frontiers Production Office.
Erratum for
-
Comparison of bleeding risk and hypofibrinogenemia-associated risk factors between tigecycline with cefoperazone/sulbactam therapy and other tigecycline-based combination therapies.Front Pharmacol. 2023 Jun 7;14:1182644. doi: 10.3389/fphar.2023.1182644. eCollection 2023. Front Pharmacol. 2023. PMID: 37351509 Free PMC article.
Publication types
LinkOut - more resources
Full Text Sources
